Document is current

Article History

Received: 11 December 2023

Accepted: 24 September 2024

First Online: 1 October 2024

Declarations

:

: This investigation was reviewed and approved by the NORC IRB and determined by the University of Michigan IRBMED to be an exempt study (Federal Exemption 2). Participants consented per the NORC IRB.

: All authors approve of this manuscript for publication.

: KFB has received grant funding from Tryp Therapeutics for a clinical trial of psilocybin-assisted therapy and sits on a data safety and monitoring board for an ongoing clinical trial with Vireo Health (unpaid). He has received grant funding from the National Institute on Drug Abuse and the National Institutes of Arthritis, Musculoskeletal, and Skin Diseases of the National Institutes of Health. He has also received granting funding from the State of Michigan Veteran Marijuana Research Program. KFB has received speaking fees for lectures from the Medical Cannabis Research Advocacy Alliance, Providence Holy Cross Medical Center, the University of Michigan Retirees Association, and the Michigan Center of Clinical Systems Improvement. ARWP has received grant funding from the National Institute on Drug Abuse. She has also received consulting fees from Vectura Fertin Pharma. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All other authors declare no conflicts of interest.